PTCT Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial; OMER Inhibits Thrombus Formation


PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 1b/2a study in adult and pediatric patients. The placebo-controlled, randomized, multiple-dose study will enroll approximately 48 patients with SMA and investigate the safety and tolerability of an investigational survival of motor neuron 2 (SMN2) gene splicing modifier (RG7800) over 12 weeks. The achievement of this milestone triggers a $10 million payment to PTC from Roche.

“We are excited to initiate the next phase of this program and begin a trial in SMA patients with our partners,” stated Stuart Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. “We believe that the encouraging clinical results and preclinical data from relevant disease models are promising indications that the orally administered small molecule RG7800 has the potential to modify the splicing of the SMN2 gene and generate more full-length SMN mRNA in SMA patients. The advancement of this potential new treatment, which could represent the first orally available SMN2 splicing modifier for SMA, is a significant milestone for patients and their families.”

As previously reported, the Phase 1 single-ascending dose study in healthy volunteers demonstrated that all doses studied were safe, well tolerated and demonstrated a dose-dependent effect on SMN2 splicing as shown by a change in the ratio of full-length SMN2 mRNA to SMN2 mRNA without exon 7 (SMND7), which is interpreted as proof of mechanism in terms of the expected pharmacodynamic effect.

SMA is caused by a missing or defective SMN1 gene, which results in reduced levels of SMN protein. This genetic neuromuscular disease is responsible for the loss of motor neurons within the spinal cord leading to muscle atrophy and death at infant age in its most severe form. We believe the oral small molecule RG7800 may have the potential to target the underlying cause of the disorder by increasing SMN protein levels in the nervous system, muscles, and other tissues. It is estimated that one in 10,000 children in the United States are born with this rare disorder.

The SMA program was initially developed by PTC Therapeutics in partnership with the SMA Foundation. The SMA Foundation was established in 2003 to accelerate the development of a treatment for SMA. In November 2011, Roche gained an exclusive worldwide license to the PTC/ SMAF SMA program. The development of RG7800 is being led by Roche and overseen by a joint steering committee with members from Roche, PTC and the SMA Foundation.

Reviews

  • Total Score 0%
User rating: 0.00% ( 0
votes )



Leave a Reply

Your email address will not be published. Required fields are marked *